Arintra
PrivateLast Round
Series B
Aug 26, 2026
Est. Valuation
$100M
Total Funding Raised
$46.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Arintra operates in Healthcare & Life Sciences and is based in Austin, Texas. Its latest recorded funding round was a Series B round in August 2026.
Arintra is a healthcare technology company that provides a GenAI-native autonomous medical coding platform for hospitals and health systems.
Sector
Healthcare & Life Sciences
Verticals
Revenue Cycle, Medical AI, EHR & EMR, NLP & Conversational AI, Workflow Automation
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arintra Comparables
Compare Arintra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CodaMetrix | 93% | |
| Fathom | 92% | |
| Nym | 90% |
For institutional investors. Book with your work email.
Arintra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 26, 2026 | ||||
| Series A | Aug 12, 2025 | ||||
| Seed | Mar 13, 2024 | ||||
| Seed | Oct 1, 2023 | ||||
| Seed | Mar 1, 2023 | ||||
Accelerator | Mar 29, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Arintra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Define Ventures | Series B |
| Surge | Seed |
| Peak XV Partners | Seed, Series B, Series A |
| FoundersX Ventures | Seed, Series A |
| Counterpart Ventures | Series A, Series B |
| Y Combinator | Seed, Accelerator, Series A, Series B |
| Endeavor Health Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2026
$25M round led by Define Ventures.
- Jun 28, 2026
Grew 15% QoQ, from 124 to 143 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 26, 2026
Arintra raises $25M in Series B financing in California on Aug 26th '26, in a round led by Define Ventures with participation from existing investors including Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13, and Spider Capital, bringing its total funding to $51 million.
For institutional investors. Book with your work email.
Arintra Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arintra's valuation, stock price, and market status.
Is Arintra a public or private company?
Arintra is a private company.
What is the current stock price of Arintra?
Arintra is a private company, so its shares have no public market price. Caplight tracks Arintra's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arintra worth (valuation)?
Arintra's valuation is estimated at $100.0M based on funding round data.
Can I buy Arintra stock?
Arintra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arintra's last funding round?
Arintra's most recent funding round was Series B on August 26, 2026.
Who are the main investors in Arintra?
Key investors in Arintra include Define Ventures, Peak XV Partners.
Will Arintra IPO soon?
No public IPO plans have been announced for Arintra.
How can I track Arintra secondary market activity?
Caplight tracks bids, offers, and trades in Arintra's shares on secondary markets.